ALPMF Stock - Astellas Pharma Inc.
Unlock GoAI Insights for ALPMF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.91T | $1.60T | $1.52T | $1.30T | $1.25T |
| Gross Profit | $1.56T | $1.31T | $1.23T | $1.04T | $1.00T |
| Gross Margin | 81.7% | 81.8% | 81.0% | 80.5% | 80.3% |
| Operating Income | $41.04B | $25.52B | $133.03B | $220.02B | $136.05B |
| Net Income | $50.75B | $17.05B | $98.71B | $124.09B | $120.59B |
| Net Margin | 2.7% | 1.1% | 6.5% | 9.6% | 9.7% |
| EPS | $28.35 | $9.50 | $54.24 | $67.08 | $64.93 |
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
ALPMFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 23, 2026 | — | — | — | — |
Q1 2026 | Feb 2, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.20 | $0.00 | -99.0% | ✗ MISS |
Q3 2025 | Jul 30, 2025 | $0.14 | $0.26 | +90.9% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $0.14 | $0.29 | +105.1% | ✓ BEAT |
Q1 2025 | Feb 3, 2025 | $0.00 | $-0.36 | -36533.3% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $0.15 | $0.13 | -11.2% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $0.09 | $0.14 | +59.1% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $-0.02 | $-0.12 | -585.1% | ✗ MISS |
Q1 2024 | Feb 5, 2024 | $0.12 | $0.07 | -41.6% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $0.20 | $-0.01 | -102.8% | ✗ MISS |
Q3 2023 | Aug 1, 2023 | $0.22 | $0.13 | -41.7% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $-0.03 | $-0.19 | -512.1% | ✗ MISS |
Q1 2023 | Feb 6, 2023 | $0.30 | $0.20 | -32.5% | ✗ MISS |
Q4 2022 | Oct 31, 2022 | $0.23 | $0.27 | +17.0% | ✓ BEAT |
Q3 2022 | Aug 1, 2022 | $0.15 | $0.10 | -33.9% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $0.19 | $-0.03 | -118.3% | ✗ MISS |
Q1 2022 | Feb 2, 2022 | $0.29 | $0.29 | -2.2% | ✗ MISS |
Q4 2021 | Oct 29, 2021 | — | $0.19 | — | — |
Q3 2021 | Jul 30, 2021 | — | $0.15 | — | — |
Frequently Asked Questions about ALPMF
What is ALPMF's current stock price?
What is the analyst price target for ALPMF?
What sector is Astellas Pharma Inc. in?
What is ALPMF's market cap?
Does ALPMF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALPMF for comparison